Table 5

 Adjusted OR for duration of use of statins on survival determined by the nested case–control analysis

Duration (months)Proportion of cases (n = 2266)Proportion of controls (n = 9064)OR*95% CIp Value
*OR adjusted for co-morbidity (diabetes, hypertension, CCF, myocardial infarction, cancer), angiotensin converting enzyme inhibitors, aspirin, β blockers, calcium channel blockers, smoking, body mass index, and deprivation (Townsend score in fifths).
No statins1821 (80.4%)6761 (74.6%)1.00
1–12217 (9.6%)967 (10.7%)0.800.66 to 0.970.020
13–2495 (4.2%)529 (5.8%)0.600.46 to 0.78<0.001
24–3657 (2.5%)348 (3.8%)0.470.34 to 0.67<0.001
37–4846 (2.0%)226 (2.5%)0.480.32 to 0.71<0.001
49–6023 (1.0%)139 (1.5%)0.540.32 to 0.920.021
>607 (0.3%)94 (1.0%)0.200.08 to 0.47<0.001